IDEAYA Biosciences announces Phase 1/2 expansion for IDE397 and Trodelvy combination in MTAP-deletion urothelial cancer

CAR-T Digest - August 2020

10 Apr 2025: IDEAYA Biosciences announces Phase 1/2 expansion for IDE397 and Trodelvy combination in MTAP-deletion urothelial cancer

IDEAYA Biosciences has begun a Phase 1/2 trial of a MAT2A inhibitor, IDE397, with Gilead’s Trodelvy for MTAP-deletion urothelial cancer, based on promising safety and efficacy data
IDE397 is a selective small molecule targeting MAT2A, intended for patients with solid tumors that exhibit MTAP-deletion, which occurs in approximately 26% of UC cases
The use of Trodelvy in MTAP-deletion UC is investigational, and this combination has not yet been approved or fully validated for safety and efficacy
IDEAYA also plans to initiate a clinical trial combining IDE397 with its own PRMT5 inhibitor, IDE892, in the second half of 2025, as part of a broader development strategy
A clinical update on the IDE397 and Trodelvy combination is expected in 2025, alongside ongoing monotherapy expansion studies in MTAP-deletion NSCLC and UC